Skip to main content

14-09-2022 | ESMO 2022 | Conference coverage | Video

Exploratory data suggest potential of epigenetic biomarkers in advanced UC

share
SHARE

Joaquim Bellmunt outlines the latest analysis from the JAVELIN Bladder 100 trial pointing to a potential role for chromatin conformation loops as a biomarker of maintenance avelumab benefit in advanced urothelial cancer (3:42).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany